Trial Profile
An Open Label Single Dose Phase I Trial of 120 mg and 240 mg BI 201335 Soft Gel Capsules to Study Pharmacokinetic Properties and Safety in Patients With Compensated Liver Cirrhosis in Historical Comparison With 1220.2
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Faldaprevir (Primary)
- Indications Hepatitis C; Liver cirrhosis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 03 Aug 2013 New trial record